Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Total Liabilities (2018 - 2025)

TransMedics has reported Total Liabilities over the past 8 years, most recently at $595.3 million for Q4 2025.

  • Quarterly results put Total Liabilities at $595.3 million for Q4 2025, up 3.44% from a year ago — trailing twelve months through Dec 2025 was $595.3 million (up 3.44% YoY), and the annual figure for FY2025 was $595.3 million, up 3.44%.
  • Total Liabilities for Q4 2025 was $595.3 million at TransMedics, up from $590.8 million in the prior quarter.
  • Over the last five years, Total Liabilities for TMDX hit a ceiling of $595.3 million in Q4 2025 and a floor of $48.1 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $554.0 million (2023), compared with a mean of $345.6 million.
  • Biggest five-year swings in Total Liabilities: dropped 4.24% in 2021 and later surged 721.42% in 2023.
  • TransMedics' Total Liabilities stood at $67.0 million in 2021, then skyrocketed by 33.91% to $89.8 million in 2022, then skyrocketed by 533.66% to $568.8 million in 2023, then increased by 1.17% to $575.5 million in 2024, then increased by 3.44% to $595.3 million in 2025.
  • The last three reported values for Total Liabilities were $595.3 million (Q4 2025), $590.8 million (Q3 2025), and $572.4 million (Q2 2025) per Business Quant data.